

# Friedhelm Raue

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6080501/publications.pdf>

Version: 2024-02-01

223  
papers

11,455  
citations

41344

49  
h-index

31849

101  
g-index

282  
all docs

282  
docs citations

282  
times ranked

5700  
citing authors

#	ARTICLE	IF	CITATIONS
1	CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5658-5671.	3.6	1,782
2	Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid, 2015, 25, 567-610.	4.5	1,738
3	Early Malignant Progression of Hereditary Medullary Thyroid Cancer. New England Journal of Medicine, 2003, 349, 1517-1525.	27.0	506
4	The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA - Journal of the American Medical Association, 1996, 276, 1575-9.	7.4	289
5	Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. Journal of Internal Medicine, 1995, 238, 343-346.	6.0	263
6	A New Hot Spot for Mutations in the RET Protooncogene Causing Familial Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2A1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 770-774.	3.6	224
7	A study of complaints and their relation to vertebral destruction in patients with osteoporosis. Bone and Mineral, 1990, 8, 217-229.	1.9	179
8	Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clinical Endocrinology, 1995, 43, 123-127.	2.4	171
9	Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes and Cancer, 1995, 12, 209-212.	2.8	160
10	External radiotherapy of pituitary adenomas. International Journal of Radiation Oncology Biology Physics, 1995, 33, 307-314.	0.8	154
11	Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene, 1999, 18, 1369-1373.	5.9	137
12	Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. The Clinical Investigator, 1993, 71, 7-12.	0.6	130
13	Prognostic value of codon 918 (ATG-ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. International Journal of Cancer, 2001, 95, 62-66.	5.1	127
14	Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. European Journal of Endocrinology, 2006, 155, 229-236.	3.7	124
15	Calcitonin Measurement to Detect Medullary Thyroid Carcinoma in Nodular Goiter: German Evidence-Based Consensus Recommendation. Experimental and Clinical Endocrinology and Diabetes, 2004, 112, 52-58.	1.2	122
16	Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clinical Endocrinology, 2007, 67, 070621212019004-???	2.4	121
17	Update multiple endocrine neoplasia type 2. Familial Cancer, 2010, 9, 449-457.	1.9	120
18	Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Research, 1996, 56, 2167-70.	0.9	120

#	ARTICLE	IF	CITATIONS
19	Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. Journal of Internal Medicine, 1995, 238, 369-373.	6.0	119
20	Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 1780-1783.	3.6	117
21	Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Human Mutation, 2011, 32, 51-58.	2.5	117
22	Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC. Molecular and Cellular Endocrinology, 2010, 322, 2-7.	3.2	110
23	Thyroid Cancer: Risk-Stratified Management and Individualized Therapy. Clinical Cancer Research, 2016, 22, 5012-5021.	7.0	108
24	Multiple Endocrine Neoplasia Type 2: Clinical Features and Screening. Endocrinology and Metabolism Clinics of North America, 1994, 23, 137-156.	3.2	101
25	Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. European Journal of Endocrinology, 2007, 157, 215-220.	3.7	100
26	Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 424-430.	6.4	99
27	Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Journal of Cancer Research and Clinical Oncology, 1990, 116, 21-23.	2.5	93
28	Multiple endocrine neoplasia type 2. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 371-387.	4.7	92
29	Prevalence and Clinical Spectrum of Nonsecretory Medullary Thyroid Carcinoma in a Series of 839 Patients with Sporadic Medullary Thyroid Carcinoma. Thyroid, 2013, 23, 294-300.	4.5	90
30	Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones, 2009, 8, 23-28.	1.9	86
31	Activating mutations in the calcium-sensing receptor: genetic and clinical spectrum in 25 patients with autosomal dominant hypocalcaemia - a German survey. Clinical Endocrinology, 2011, 75, 760-765.	2.4	80
32	Basal and Stimulated Calcitonin and Procalcitonin by Various Assays in Patients with and without Medullary Thyroid Cancer. Clinical Chemistry, 2011, 57, 467-474.	3.2	75
33	Localization of Occult Persisting Medullary Thyroid Carcinoma Before Microsurgical Reoperation: High Sensitivity of Selective Venous Catheterization. Thyroid, 1992, 2, 113-117.	4.5	71
34	German medullary thyroid carcinoma/multiple endocrine neoplasia registry. Langenbeck's Archives of Surgery, 1998, 383, 334-336.	1.9	71
35	Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clinical Endocrinology, 1995, 42, 31-37.	2.4	70
36	Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium. European Journal of Endocrinology, 2013, 168, 307-314.	3.7	70

#	ARTICLE	IF	CITATIONS
37	Novel Inactivating Mutations of the Calcium-Sensing Receptor: The Calcimimetic NPS R-568 Improves Signal Transduction of Mutant Receptors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4797-4803.	3.6	66
38	Increased prevalence of colonic adenomas in patients with acromegaly. <i>European Journal of Endocrinology</i> , 1994, 131, 235-237.	3.7	64
39	Genotype-phenotype correlation in multiple endocrine neoplasia type 2. <i>Clinics</i> , 2012, 67, 69-75.	1.5	64
40	Parathyroid hormone-related peptide and 8701-BC breast cancer cell growth and invasion in vitro: evidence for growth-inhibiting and invasion-promoting effects. <i>Molecular and Cellular Endocrinology</i> , 1995, 111, 225-232.	3.2	63
41	Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma. Three-year results. <i>Cancer</i> , 1993, 72, 3685-3693.	4.1	60
42	Response to methimazole in Graves' disease. <i>Clinical Endocrinology</i> , 1995, 43, 257-263.	2.4	58
43	Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791*. <i>Clinical Endocrinology</i> , 2008, 69, 259-263.	2.4	57
44	Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 76, 801-803.	3.6	55
45	Inactivating calcium-sensing receptor mutations in patients with primary hyperparathyroidism. <i>Clinical Endocrinology</i> , 2011, 75, 50-55.	2.4	53
46	Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. <i>Surgery</i> , 1995, 118, 1099-1104.	1.9	52
47	Developing Effective Screening Strategies in Multiple Endocrine Neoplasia Type 1 (MEN 1) on the Basis of Clinical and Sequencing Data of German Patients with MEN 1. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2007, 115, 509-517.	1.2	52
48	Novel Activating Mutations of the Calcium-Sensing Receptor: The Calcilytic NPS-2143 Mitigates Excessive Signal Transduction of Mutant Receptors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E229-E233.	3.6	51
49	Performance evaluation of automated assays for $\hat{2}$ -CrossLaps, N-MID-Osteocalcin and intact parathyroidhormone (BIOROSE Multicenter Study). <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 90-5.	2.3	50
50	Changing Concepts in the Management of Hereditary and Sporadic Medullary Thyroid Carcinoma. <i>Endocrinology and Metabolism Clinics of North America</i> , 1990, 19, 613-635.	3.2	48
51	Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation. <i>Recent Results in Cancer Research</i> , 2015, 204, 139-156.	1.8	46
52	Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC&gt;TGG) mutation. <i>Endocrine-Related Cancer</i> , 2008, 15, 1035-1041.	3.1	45
53	THE HYPERCALCAEMIC SYNDROME IN RATS BEARING THE WALKER CARCINOSARCOMA 256. <i>European Journal of Endocrinology</i> , 1975, 78, 613-624.	3.7	42
54	Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma. <i>Recent Results in Cancer Research</i> , 2015, 204, 61-90.	1.8	42

#	ARTICLE	IF	CITATIONS
55	Chromogranin A as Tumor Marker in Medullary Thyroid Carcinoma. <i>Thyroid</i> , 1992, 2, 5-10.	4.5	41
56	Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1998, 106, 353-359.	1.2	41
57	Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma.. <i>European Journal of Endocrinology</i> , 2008, 158, 811-816.	3.7	41
58	Synaptophysin Identified in Metastases of Neuroendocrine Tumors by Immunocytochemistry and Immunoblotting. <i>American Journal of Clinical Pathology</i> , 1987, 88, 560-569.	0.7	39
59	Multiple Endocrine Neoplasia Type 2: 2007 Update. <i>Hormone Research in Paediatrics</i> , 2007, 68, 101-104.	1.8	39
60	Diagnosis and management of pheochromocytomas in patients with multiple endocrine neoplasia type 2â€™ relevance of specific mutations in the RET proto-oncogene. <i>European Journal of Endocrinology</i> , 1996, 135, 222-225.	3.7	38
61	Circulating levels of midregional parathyroid hormoneâ€™related protein in hypercalcaemia of malignancy. <i>Clinical Endocrinology</i> , 1992, 37, 290-297.	2.4	37
62	The Role of the Extracellular Calcium-Sensing Receptor in Health and Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2006, 114, 397-405.	1.2	37
63	Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma. <i>Journal of the Endocrine Society</i> , 2018, 2, 933-943.	0.2	37
64	Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 459-469.	4.5	37
65	Papillary Carcinoma in an Ectopic Thyroid. <i>Hormone Research</i> , 1991, 35, 86-88.	1.8	36
66	Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribution to calcitonin secretion. <i>Endocrinology</i> , 1996, 137, 3842-3848.	2.8	36
67	Reversible Diminished Calcitonin Secretion in the Rat during Chronic Hypercalcemia*. <i>Endocrinology</i> , 1984, 115, 2362-2367.	2.8	35
68	CDC73-related hereditary hyperparathyroidism: five new mutations and the clinical spectrum. <i>European Journal of Endocrinology</i> , 2011, 165, 477-483.	3.7	35
69	Early diagnosis of the multiple endocrine neoplasia type 2 syndrome: consensus statement. <i>European Journal of Clinical Investigation</i> , 1992, 22, 755-760.	3.4	34
70	Is Routine Screening of Young Asymptomatic MEN1â€™Patients Necessary?. <i>World Journal of Surgery</i> , 2017, 41, 2026-2032.	1.6	33
71	Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codonâ€™specific penetrance and changes in management during the last four decades. <i>Clinical Endocrinology</i> , 2017, 87, 320-326.	2.4	32
72	Clinical significance of antibodies against calcitonin. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1995, 103, 345-351.	1.2	31

#	ARTICLE	IF	CITATIONS
73	Regulation of calcitonin gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 1233-1237.	2.8	31
74	Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer. <i>Clinical Endocrinology</i> , 2012, 76, 691-697.	2.4	31
75	Long-Term Follow-up in Medullary Thyroid Carcinoma. <i>Recent Results in Cancer Research</i> , 2015, 204, 207-225.	1.8	31
76	Heterozygous inactivating CaSR mutations causing neonatal hyperparathyroidism: function, inheritance and phenotype. <i>European Journal of Endocrinology</i> , 2016, 175, 421-431.	3.7	31
77	In vitro detection of neutralizing antibodies after treatment of paget's disease of bone with nasal salmon calcitonin. <i>Journal of Bone and Mineral Research</i> , 1990, 5, 387-391.	2.8	28
78	Coincidence of Multiple Endocrine Neoplasia Types 1 and 2: Mutations in the RET Protooncogene and MEN1 Tumor Suppressor Gene in a Family Presenting with Recurrent Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4063-4067.	3.6	28
79	United States and European Multicenter Prospective Study for the Analytical Performance and Clinical Validation of a Novel Sensitive Fully Automated Immunoassay for Calcitonin. <i>Clinical Chemistry</i> , 2017, 63, 1489-1496.	3.2	28
80	Severe form of thyroid hormone resistance in a patient with homozygous/hemizygous mutation of T3 receptor gene. <i>European Journal of Endocrinology</i> , 2004, 150, 819-823.	3.7	27
81	Down-regulation of calcitonin receptors in T47D cells by internalization of calcitonin-receptor complexes. <i>Molecular and Cellular Endocrinology</i> , 1988, 58, 9-15.	3.2	26
82	Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation. <i>Surgery</i> , 2004, 136, 1083-1087.	1.9	25
83	Long-Term Survivorship in Multiple Endocrine Neoplasia Type 2B Diagnosed Before and in the New Millennium. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 235-243.	3.6	25
84	Change in the spectrum of RET mutations diagnosed between 1994 and 2006. <i>Clinical Laboratory</i> , 2007, 53, 273-82.	0.5	25
85	Mutational Analysis of the PHEX Gene: Novel Point Mutations and Detection of Large Deletions by MLPA in Patients with X-Linked Hypophosphatemic Rickets. <i>Calcified Tissue International</i> , 2009, 85, 211-220.	3.1	24
86	Are commonly recommended dosages for vitamin D supplementation too low? Vitamin D status and effects of supplementation on serum 25-hydroxyvitamin D levels – an observational study during clinical practice conditions. <i>Osteoporosis International</i> , 2011, 22, 231-240.	3.1	24
87	Amino Alcohol- (NPS-2143) and Quinazolinone-Derived Calcilytics (ATF936 and AXT914) Differentially Mitigate Excessive Signalling of Calcium-Sensing Receptor Mutants Causing Bartter Syndrome Type 5 and Autosomal Dominant Hypocalcemia. <i>PLoS ONE</i> , 2014, 9, e115178.	2.5	23
88	Clinical Features of Multiple Endocrine Neoplasia Type 1 and Type 2. <i>Hormone Research</i> , 1992, 38, 31-35.	1.8	22
89	Hypercalcitoninaemia in patients with pheochromocytoma. <i>Klinische Wochenschrift</i> , 1978, 56, 697-701.	0.6	21
90	Neutralizing Antibodies Against Calcitonin. <i>Hormone and Metabolic Research</i> , 1993, 25, 486-488.	1.5	21

#	ARTICLE	IF	CITATIONS
91	New operative strategy in the treatment of metastasizing medullary carcinoma of the thyroid. European Journal of Surgical Oncology, 1990, 16, 366-9.	1.0	21
92	Calcitonin in Human Pathophysiology. Hormone Research, 1984, 20, 65-73.	1.8	20
93	Rhythmic oscillations of cytosolic free calcium in rat C-cells. Molecular and Cellular Endocrinology, 1989, 64, 267-270.	3.2	20
94	Cyclic AMP Formation in Rat Bone and Kidney Cells Is Stimulated Equally by Parathyroid Hormone-Related Protein (PTHrP) 1-34 and PTH 1-34 <sup>*</sup> . Experimental and Clinical Endocrinology and Diabetes, 1993, 101, 150-155.	1.2	20
95	The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases. Archives of Internal Medicine, 1992, 152, 1250-2.	3.8	20
96	Long-term excess of endogenous calcitonin in patients with medullary thyroid carcinoma does not affect bone mineral density. Journal of Endocrinology, 1992, 134, 141-147.	2.6	19
97	Homologous radioimmunoassay for human parathyrin (residues 53-84).. Clinical Chemistry, 1982, 28, 1749-1753.	3.2	18
98	Formation of neutralizing antibodies after treatment with human calcitonin. American Journal of Medicine, 1993, 95, 439-442.	1.5	18
99	Levels of Parathyroid Hormone-Related Protein (PTHrP) in Hypercalcemia of Malignancy Are not Lowered by Treatment With the Bisphosphonate BM 21.0955. Hormone and Metabolic Research, 1993, 25, 40-44.	1.5	18
100	Norepinephrine induced calcitonin secretion in rat medullary thyroid carcinoma 6â€”23 cells: Interaction between intracellular calcium and cAMP. Experimental and Clinical Endocrinology and Diabetes, 1996, 104, 43-49.	1.2	18
101	Long-Term Outcomes and Aggressiveness of Hereditary Medullary Thyroid Carcinoma: 40 Years of Experience at One Center. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4264-4272.	3.6	18
102	The potential value of somatostatin receptor scintigraphy in medullary thyroid carcinoma. Nuclear Medicine Communications, 1993, 14, 439-445.	1.1	17
103	Microsurgical neck dissection for metastasizing medullary thyroid carcinoma. European Journal of Surgical Oncology, 1995, 21, 195-197.	1.0	17
104	New Mutations in the RET Protooncogene-L881V â€” Associated with Medullary Thyroid Carcinoma and -R770Q â€” in a Patient with Mixed Medullar/Follicular Thyroid Tumour. Experimental and Clinical Endocrinology and Diabetes, 2010, 118, 550-553.	1.2	17
105	Multiple endocrine neoplasia type 2. Clinical features and screening. Endocrinology and Metabolism Clinics of North America, 1994, 23, 137-56.	3.2	17
106	Inhibition of Ca <sup>2+</sup> -induced calcitonin secretion by somatostatin: Roles of voltage dependent Ca <sup>2+</sup> channels and G-proteins. Cellular Signalling, 1992, 4, 77-85.	3.6	16
107	Increased incidence of cardiovascular diseases in primary hyperparathyroidism - a cause for more aggressive treatment?. European Journal of Clinical Investigation, 1998, 28, 277-278.	3.4	16
108	Rapid Response to Sorafenib in Metastatic Medullary Thyroid Carcinoma. Experimental and Clinical Endocrinology and Diabetes, 2011, 119, 151-155.	1.2	16



#	ARTICLE	IF	CITATIONS
109	Medullary Thyroid Carcinoma: Imaging. <i>Recent Results in Cancer Research</i> , 2015, 204, 91-116.	1.8	16
110	Long-Term Follow-Up and Treatment of Postoperative Permanent Hypoparathyroidism in Patients with Medullary Thyroid Carcinoma: Differences in Complete and Partial Disease. <i>Hormone and Metabolic Research</i> , 2016, 48, 806-813.	1.5	16
111	Radioimmunoassay for Human Parathyroid Hormone for Differentiation between Patients with Hypoparathyroidism, Hyperparathyroidism and Normals. <i>Hormone and Metabolic Research</i> , 1979, 11, 375-376.	1.5	15
112	Reversible desensitization of calcitonin secretion by repetitive stimulation with calcium. <i>Molecular and Cellular Endocrinology</i> , 1989, 63, 263-266.	3.2	14
113	K <sub>1/2</sub> berling-Dunnigan syndrome: A rare cause of generalized muscular hypertrophy. , 1996, 19, 843-847.		14
114	Prophylactic thyroidectomy in MEN IIA: does the calcitonin level correlate with tumor spread?. <i>Langenbecks Archiv Fur Chirurgie</i> , 1998, 383, 170.	0.2	14
115	Multiple endocrine neoplasia type 2 (MEN 2). <i>European Journal of Cancer</i> , 2009, 45, 267-273.	2.8	14
116	Role of voltage-dependent calcium channels in secretion of calcitonin from human medullary thyroid carcinoma cells. <i>Klinische Wochenschrift</i> , 1989, 67, 635-639.	0.6	13
117	Tumor necrosis factor $\alpha$ inhibits the stimulatory effect of the parathyroid hormone-related protein on cyclic AMP formation in osteoblast-like cells via protein kinase C. <i>Biochemical and Biophysical Research Communications</i> , 1992, 182, 341-347.	2.1	13
118	A new in vitro bioassay for human calcitonin: validation and comparison to the rat hypocalcemia bioassay. <i>Bone and Mineral</i> , 1992, 17, 65-74.	1.9	13
119	Extracellular Calcium Sensitivity and Voltage-Dependent Calcium Channels in C Cells*. <i>Endocrine Reviews</i> , 1995, 16, 752-764.	20.1	13
120	Glucocorticoids decrease the production of parathyroid hormone-related protein in vitro but not in vivo in the walker carcinosarcoma 256 rat model. <i>Bone</i> , 1996, 18, 315-319.	2.9	13
121	Routine calcitonin determination in thyroid nodules – an effective approach?. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1998, 106, 289-291.	1.2	13
122	Acute Effect of 1,25-Dihydroxy-Vitamin D <sub>3</sub> on Calcitonin Secretion in Rats. <i>Hormone and Metabolic Research</i> , 1983, 15, 208-209.	1.5	12
123	Action of Calcitonin Gene-Related Peptide at the Calcitonin Receptor of the T47D Cell Line. <i>Hormone and Metabolic Research</i> , 1987, 19, 563-564.	1.5	12
124	Superior local tolerability of human versus salmon calcitonin preparations in young healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 1991, 41, 211-215.	1.9	12
125	Inhibitory effect of somatostatin on cAMP accumulation and calcitonin secretion in C-cells: Involvement of pertussis toxin-sensitive G-proteins. <i>Molecular and Cellular Endocrinology</i> , 1992, 86, 213-219.	3.2	12
126	Presymptomatic genetic screening in families with multiple endocrine neoplasia type 2. <i>Journal of Molecular Medicine</i> , 1995, 73, 229-33.	3.9	12



#	ARTICLE	IF	CITATIONS
127	Results and follow-up in eleven MEN 2A gene carriers after prophylactic thyroidectomy. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1997, 105, 76-78.	1.2	12
128	Neuron-specific enolase in medullary thyroid carcinoma: immunohistochemical demonstration, but no significance as serum tumor marker. <i>Journal of Cancer Research and Clinical Oncology</i> , 1987, 113, 599-602.	2.5	11
129	1,25-Dihydroxyvitamin D3 suppresses dexamethasone effects on calcitonin secretion. <i>Molecular and Cellular Endocrinology</i> , 1990, 71, R13-R18.	3.2	11
130	Application of genetic screening in families with hereditary medullary thyroid carcinoma*. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1996, 104, 108-110.	1.2	11
131	Chemotherapie bei SchilddrÃ¼senkarzinomen: Indikation und Ergebnisse. <i>Onkologie</i> , 1997, 3, 55-58.	0.7	11
132	Procalcitonin measured by three different assays is an excellent tumor marker for the follow-up of patients with medullary thyroid carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1861-1868.	2.3	11
133	Importance of early diagnosis and follow-up in multiple endocrine neoplasia (MEN II B). <i>European Journal of Pediatrics</i> , 1984, 143, 112-116.	2.7	10
134	Evaluation of sensitive PDN-21 (Katacalcin) determination as tumor marker in medullary thyroid carcinoma. <i>Journal of Endocrinological Investigation</i> , 1992, 15, 93-98.	3.3	10
135	Levels of parathyroid hormone-related protein in hypercalcemia of malignancy: comparison of midregional radioimmunoassay and two-site immunoradiometric assay. <i>The Clinical Investigator</i> , 1993, 71, 31-36.	0.6	10
136	Regulation of Calcitonin Secretion in Vitro. <i>Hormone and Metabolic Research</i> , 1993, 25, 473-476.	1.5	10
137	Major role of dihydropyridine-sensitive Ca <sup>2+</sup> channels in Ca(2+)-induced calcitonin secretion. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1993, 264, E354-E360.	3.5	10
138	Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2239-e2246.	3.6	10
139	Similar Stage-dependent Survival and Outcome in Sporadic and Hereditary Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3582-e3591.	3.6	10
140	Somatostatin inhibits the norepinephrine-activated calcium channels in rMTC 6â€“23 cells: possible involvement of a pertussis toxin-sensitive G-protein. <i>European Journal of Endocrinology</i> , 1992, 127, 378-384.	3.7	9
141	Effects of passive immunization against parathyroid hormone-related protein: PTHrP is the responsible factor in mediating hypercalcemia in the walker carcinosarcoma 256 rat model. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 7-16.	2.8	9
142	Calcitonin measurement in pediatrics: reference ranges are gender-dependent, validation in medullary thyroid cancer and thyroid diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1242-1250.	2.3	9
143	Importance of ultrasound examination for the follow-up of medullary thyroid carcinoma: comparison with other localization methods. <i>Henry Ford Hospital Medical Journal</i> , 1987, 35, 122-3.	0.1	9
144	Enhanced calcitonin secretion in the rat after parathyroidectomy and during chronic calcium deprivation. <i>European Journal of Clinical Investigation</i> , 1988, 18, 284-289.	3.4	8

#	ARTICLE	IF	CITATIONS
145	Internalization of calcitonin receptors in primary rat kidney cell cultures. <i>European Journal of Endocrinology</i> , 1990, 122, 255-262.	3.7	8
146	Epidemiological Aspects of Hypercalcemia of Malignancy. <i>Recent Results in Cancer Research</i> , 1994, 137, 99-106.	1.8	8
147	Different effects of hypercalcemic state induced by walker tumor (HWCS 256) and 1,25 (OH)D3 intoxication on rat thyroid C cells. <i>Histochemistry</i> , 1984, 80, 503-508.	1.9	7
148	Sensitive Homologous Radioimmunoassay for Human Parathyroid Hormone to Diagnose Hypoparathyroid Conditions. <i>Annals of Clinical Biochemistry</i> , 1987, 24, 608-613.	1.6	7
149	Effects of $17\beta$ -estradiol on calcitonin secretion and content in a human medullary thyroid carcinoma cell line. <i>Journal of Bone and Mineral Research</i> , 1991, 6, 1191-1196.	2.8	7
150	Medullary thyroid cancer with ectopic Cushing's syndrome: A multicentre case series. <i>Clinical Endocrinology</i> , 2022, 96, 847-856.	2.4	7
151	Changing concepts in the management of hereditary and sporadic medullary thyroid carcinoma. <i>Endocrinology and Metabolism Clinics of North America</i> , 1990, 19, 613-35.	3.2	7
152	Determination of Serum Calcitonin by Immunometric Two-Site Assays in Normal Subjects and Patients with Medullary Thyroid Carcinoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 1992, 30, 831-5.	2.3	6
153	Development and Validation of an Assay to Measure Bioactivity of Human Calcitonin in Vitro Using T47D Cell Membranes. <i>Analytical Biochemistry</i> , 1993, 212, 91-97.	2.4	6
154	Diminished Calcitonin Secretion After Ovariectomy Without Apparent Reduction in Calcitonin Content in the Rat. <i>Hormone and Metabolic Research</i> , 1993, 25, 389-390.	1.5	6
155	Homologous desensitization of calcitonin receptors and calcitonin-dependent adenylate cyclase in T47D cells. <i>European Journal of Endocrinology</i> , 1993, 128, 373-378.	3.7	6
156	Evaluation of Somatostatin as a Plasma Tumor Marker in Medullary Thyroid Carcinoma. <i>Thyroid</i> , 1995, 5, 287-291.	4.5	6
157	Adenosine A1-Receptors Inhibit cAMP and $Ca^{2+}$ -Mediated Calcitonin Secretion in C-Cells. <i>Hormone and Metabolic Research</i> , 1995, 27, 408-414.	1.5	6
158	Late Diagnosis of Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2006, 114, 208-214.	1.2	6
159	Secretion of calcitonin and carcinoembryonic antigen in long-term organ culture of human medullary thyroid carcinoma: Biochemical and immunocytochemical studies. <i>Klinische Wochenschrift</i> , 1985, 63, 205-210.	0.6	5
160	In Vitro Secretion of Calcitonin from a Rat C Cell Line:. <i>Hormone and Metabolic Research</i> , 1992, 24, 272-275.	1.5	5
161	Drug Therapy of Hypercalcemia Due to Malignancy. <i>Recent Results in Cancer Research</i> , 1994, 137, 138-160.	1.8	5
162	Pheochromocytoma in Multiple Endocrine Neoplasia. <i>Cardiology</i> , 1985, 72, 147-149.	1.4	4

#	ARTICLE	IF	CITATIONS
163	Procollagen-III peptide serum levels in Paget's disease of the bone. <i>Klinische Wochenschrift</i> , 1987, 65, 174-178.	0.6	4
164	Long-Term Exposure to SMS 201-995 Inhibits Proliferation and Calcitonin Release in Neoplastic C-Cells. <i>Hormone and Metabolic Research</i> , 1993, 25, 528-531.	1.5	4
165	Primary hyperparathyroidism—what the nephrologist should know—an update. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 696-699.	0.7	4
166	Clinical utility gene card for: multiple endocrine neoplasia type 2. <i>European Journal of Human Genetics</i> , 2012, 20, 3-3.	2.8	4
167	Regulation of Calcitonin Secretion and Calcitonin Gene Expression. <i>Recent Results in Cancer Research</i> , 1992, 125, 1-18.	1.8	4
168	Age-Related Association of Calcitonin with Parameters of Anthropometry, Bone and Calcium Metabolism during Childhood. <i>Hormone Research in Paediatrics</i> , 2020, 93, 361-370.	1.8	4
169	Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors—A Retrospective Multi-Center Registry Analysis. <i>Cancers</i> , 2022, 14, 3405.	3.7	4
170	Relapsing Pheochromocytoma in a Chinese Women Caused by a Novel Mutation in Exon 6 of the SDHB Gene: A Case Report. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2007, 115, 616-618.	1.2	3
171	Medulläres Schilddrüsenskarzinom. , 2006, , 4071-4091.		3
172	In vitro secretion of peptides of the calcitonin family: calcitonin, katacalcin, and calcitonin gene-related peptide. <i>Henry Ford Hospital Medical Journal</i> , 1987, 35, 143-6.	0.1	3
173	Dynamics of osteoclasia in rats with Walker tumor. <i>Calcified Tissue Research</i> , 1976, 22, 368-370.	1.3	2
174	Metastatic C-cell carcinoma: Calcitonin and CEA production in monolayer culture. <i>Journal of Cancer Research and Clinical Oncology</i> , 1986, 111, 284-288.	2.5	2
175	Crucial Role of c-myc in 1,25(OH)2D3 Control of C-Cell-Carcinoma Proliferation. <i>Biochemical and Biophysical Research Communications</i> , 1995, 213, 922-927.	2.1	2
176	Biochemical parameters in diagnosis and follow-up of patients with multiple endocrine neoplasia type 2. <i>Acta Chirurgica Austriaca</i> , 1997, 29, 9-11.	0.2	2
177	Prophylactic thyroidectomy in multiple endocrine neoplasia type 2. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 867-874.	2.4	2
178	A Novel Mutation of the Calcium Sensing Receptor Gene in a Franconian Kindred: Heterozygous Mutation c.1697_1698delTG Exon 6. <i>Hormone and Metabolic Research</i> , 2017, 49, 142-146.	1.5	2
179	CT- and ultrasound-characteristics of hepatic lesions in patients with multiple endocrine neoplasia syndrome. A retrospective image review of 25 cases. <i>PLoS ONE</i> , 2019, 14, e0212865.	2.5	2
180	Postsurgical Follow-Up and Management. <i>Recent Results in Cancer Research</i> , 1992, 125, 197-211.	1.8	2

#	ARTICLE	IF	CITATIONS
181	Inherited Thyroxine-Binding Globuline Excess. Experimental and Clinical Endocrinology and Diabetes, 1986, 88, 237-241.	1.2	1
182	Surgical Therapy and Prognostic Factors in Medullary Thyroid Carcinoma (MTC). Current Evaluation of the German MTC Study Group. Oncology Research and Treatment, 1994, 17, 594-599.	1.2	1
183	Asymptomatic primary hyperparathyroidism - need to treat?. Experimental and Clinical Endocrinology and Diabetes, 2000, 108, 247-248.	1.2	1
184	Medikamentöse Therapie beim medullären Schilddrüsenkarzinom. , 0, , .		1
185	Calcitonin Screening in Nodular Goiter – Upper Limits. Deutsches Arzteblatt International, 2018, 115, 221.	0.9	1
186	Endocrine Aspects of Medullary Thyroid Carcinoma. Recent Results in Cancer Research, 1990, 118, 64-69.	1.8	1
187	Diagnosis of Medullary Thyroid Cancer. , 2001, , 239-249.		1
188	CaSR mutants disrupting the disulfide bond between C582 and C568 in the cysteine-rich domain of the CaSR do not act as dominant negative mutants. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	1
189	COMPARISON OF BIOASSAY AND RADIOIMMUNOASSAY FOR CALCITONIN IN MEDULLARY CARCINOMA OF THE THYROID. European Journal of Endocrinology, 1975, 80, S34.	3.7	1
190	Calcitonin secretion from a rat C-cell-line: synergistic stimulatory effects of glucagon and calcium, Bay K 8644 or A 23187, respectively. European Journal of Endocrinology, 1988, 117, S66.	3.7	1
191	Functional analysis of six novel mutations of the calcium-sensing receptor in familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, .	1.2	1
192	Nebenschilddrüsenkarzinom und medulläres Schilddrüsenkarzinom. , 1987, , 83-92.		1
193	Screening for MEN 2 with Biochemical and Genetic Markers. Recent Results in Cancer Research, 1992, 125, 105-123.	1.8	1
194	Extracellular calcium sensitivity and voltage-dependent calcium channels in C cells. , 1995, 16, 752-764.		1
195	Measurement of free cytosolic calcium in single cells: method and application. Methods and Findings in Experimental and Clinical Pharmacology, 1992, 14, 327-32.	0.8	1
196	Influence of chronic hypocalcemia and low calcium diet on calcitonin secretion in the rat. European Journal of Endocrinology, 1986, 113, S199-S200.	3.7	0
197	Mutations in the RET Proto-Oncogene in German Families with Multiple Endocrine Neoplasia Type 2. , 1996, , 119-121.		0
198	Influence of Dexamethasone and 1,25-Dihydroxyvitamin D on Walker Carcinosarcoma 256 Growth and Parathyroid Hormone Related Protein Secretion. Hormone and Metabolic Research, 1996, 28, 209-209.	1.5	0

#	ARTICLE	IF	CITATIONS
199	The antihypercalcemic action of gallium-nitrate is not due to inhibition of parathormone or parathormone-related protein secretion in rats. <i>European Journal of Cancer</i> , 1997, 33, S179.	2.8	0
200	The Calcium-Sensing Receptor: Physiology and Pathophysiology. , 2012, , 69-90.		0
201	Risk-stratified follow-up of patients with medullary thyroid carcinoma. <i>International Journal of Endocrine Oncology</i> , 2015, 2, 249-252.	0.4	0
202	Sporadisches und hereditÄres medullÄres SchilddrÄ¼sencarcinom â€” Klinik und Diagnostik. <i>Langenbecks Archiv F¼r Chirurgie Supplement</i> , 2000, , 344-349.	0.0	0
203	Hyper- und Hypoparathyreoidismus. , 2001, , 111-136.		0
204	Pitfalls in the genetic diagnosis of MEN 2. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2004, 112, .	1.2	0
205	Hyperparathyroidism-jaw tumor syndrome (HPT-JT): A case report with parathyroid carcinoma. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2007, 115, .	1.2	0
206	Significant difference in aggressiveness of medullary thyroid carcinoma in rare RET mutations (codons 790, 791, 804). <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2007, 115, .	1.2	0
207	PrimÄrer Hyperparathyreoidismus. , 2010, , 289-296.		0
208	Multiple endokrine Neoplasie. , 2010, , 475-483.		0
209	Activating Mutations of the Calcium-Sensing Receptor: The Calcilytic NPS-2143 Mitigates Excessive Signaling of Novel Mutants Causing Autosomal Dominant Hypocalcemia.. , 2010, , P1-148-P1-148.		0
210	Activating mutations of the calcium-sensing receptor: The calcilytics ATF-936 and AXT-914 attenuate mutants causing autosomal dominant hypocalcemia and Bartter syndrome type 5. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2013, 121, .	1.2	0
211	Activating CaSR mutations causing Bartter syndrome type 5 are characterized by a distinctly diminished inhibitory phosphorylation on amino acid T888. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, .	1.2	0
212	Postersession I. <i>Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin</i> , 1984, , 1207-1247.	0.0	0
213	Tumormarker beim C-Zellkarzinom der SchilddrÄ¼se: Katakalin, Kalzitonin, Kalzitonin-â€žgene-related-peptideâ€œ und karzinoembryonales Antigen. , 1987, , 258-259.		0
214	Diagnostic Value of the Peptides from the Calcitonin Gene. , 1990, , 48-59.		0
215	Tumorbedingte HyperkalzÄmie. Therapie mit Bisphosphonaten. <i>Innovative Aspekte Der Klinischen Medizin</i> , 1992, , 93-97.	0.0	0
216	1,25-Dihydroxyvitamin D3 Induces Growth of Thyroid C Cells and Inhibits Calcitonin Secretion In Vitro. , 1994, , 451-452.		0

#	ARTICLE	IF	CITATIONS
217	Spezifische ret proto-onkogen Mutationen bei verschiedenen hereditären Formen des C-Zell-Karzinoms. , 1995, , 303-306.		0
218	Medulläres Schilddrüsenskarzinom. , 1997, , 914-930.		0
219	Primärer Hyperparathyreoidismus – Internistische Therapie. , 2019, , 429-432.		0
220	Hypoparathyreoidismus. , 2019, , 433-435.		0
221	The calcitonin receptor: characterization and processing. Progress in Clinical and Biological Research, 1990, 332, 67-79.	0.2	0
222	The effect of magnesium on calcitonin secretion in rats. European Journal of Endocrinology, 1985, 110, S169-S170.	3.7	0
223	Reversible calcitonin accumulation in the C-cells of chronically parathyroidectomized rats. European Journal of Endocrinology, 1985, 110, S170-S171.	3.7	0